<DOC>
	<DOCNO>NCT00368576</DOCNO>
	<brief_summary>The purpose study compare effect SB-480848 placebo subject asthma .</brief_summary>
	<brief_title>A Study To Determine The Effect Of SB-480848 On Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Male female subject document persistent asthma least 3 month Subjects must stable , lowdose ICS minimum 4 week prior screen visit . Aged 1865 year , screen FEV1 great equal 70 % predict ( ECCS , 1993 ) Subjects must show increase FEV1 great equal 12 % ( absolute change &gt; 200mL ) within 30 minute follow inhalation 4 puff albuterol/salbutamol 1 nebulized treatment 2.5mg historical , documented evidence reversibility , within 12 month prior screen Subjects must willing replace inhaled , shortacting β2agonist study provide albuterol/salbutamol Patient must capable give informed consent comply study requirement timetable . Inclusion Criteria follow run period ( Prior randomisation ) Subjects screen base inclusion exclusion criterion note . During runin period [ Day 14 Day 1 ] , subject ask maintain diary card document number puff rescue inhale , shortacting β2agonists take , asthmarelated symptom night time awakening well morning even PEF measurement . On morning Day 0 , subject eligible randomisation study follow criterion meet : Subjects require , average less 2 puff per day study provide albuterol/ salbutamol last 7day period prior Day 0 [ Day 7 Day 1 ] Subjects asthma symptom le 5 last 7 consecutive day runin period FEV1 great equal 70 % predict ( ECCS , 1993 ) . FEV1 must within ± 15 % FEV1 value begin screen . Compliance completion diary card . Exclusion criterion : The patient life threaten asthma . A research patient must hospitalize two time last year prior Day 0 due asthma must hospitalize within 6 month prior Day 0 Subjects daily asthmarelated symptom . Subjects take medication list protocol list interval prior screen visit study : Subjects historical current evidence disease . Subjects clinically significant abnormal finding physical exam screening procedure . Subjects receive investigational product within 30 day 5 halflives [ whichever long ] prior first dose study medication Subjects test positive hepatitis C antibody , hepatitis B surface antigen HIV . Subjects history drug alcohol abuse Positive drug ( related know medication subject take time screen ) , alcohol cotinine/carbon monoxide ( CO ) test screen Day 0 Subjects history regularly drink 2 ( female ) /3 ( male ) unit alcohol day . Pregnant nursing female subject . Female subject childbearing potential unwillingness agree one method contraception list protocol . Subjects suffer medical condition opinion investigator would compromise patient safety ability comply study procedure Subjects current smoker give smoke within previous six month smoke history &gt; 10 pack year . Subjects history upper low respiratory tract infection symptom ( include common cold ) within 2 week prior first dose study medication Subjects donate 500ml blood within 56 day prior first dose study medication Subjects currently receive potent 3A4 inhibitor exclude . Subjects βadrenergic receptor blocker within 3 month prior screen visit Subjects previously hospitalize result methacholine challenge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SB-480848</keyword>
	<keyword>methacholine challenge</keyword>
	<keyword>asthma</keyword>
	<keyword>inhale steroid</keyword>
</DOC>